Basic information

Biomarker: p16

Histology type: endometrial carcinoma

Cohort characteristics

Country: Korea

Region: Daegu

Study type: retrospective study

Followed up time :

Total number Group I Group I number Group II Group II number Group III Group III number Group IV Group IV number
124 malignant lesions 36 benign lesions 62 precancerous lesions 26

Sample information

Conclusion: Our observations suggest that stromal p16 expression is involved in the development and progression of endometrial carcinoma, and raise the possibility that p16 overexpression in the peritumoral stroma is associated with aggressive oncogenic behavior of endometrial SC.

Sample type : tissue

Sample method: immunohistochemistry

Expression pattern : stromal p16 overexpression(scores ≥ 6)

Expression elevation: The estimated percentages were categorized as follows: less than 10% (score 0), 10% to 24% (score 1), 25% to 50% (score 2), or 50% or more (score 3). The staining intensity was graded as follows: negative (score 0), weak (score 1), moderate (score 2), or strong (score 3). The subcellular location of p16-positive signals (nuclear or cytoplasmic) was also estimated. The final score was calculated as the product of the percentage and staining intensity, resulting in scores of 0, 1, 2, 3, 4, 6, and 9.

Disease information

Related information

Funtion Uniprot: Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

UniProt ID: Q8N726

UniProt Link: https://www.uniprot.org/uniprotkb/Q8N726/entry#function

Biological function from UniProt: Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway

Molecular function from UniProt:

Subcellular UniProt: #Mitochondrion #Nucleus

Alternative name from UniProt:

Caution: The proteins described here are encoded by the gene CDKN2A, but are completely unrelated in terms of sequence and function to cyclin-dependent kinase inhibitor 2A (AC P42771) which is encoded by the same gene.

Recommended name: Tumor suppressor ARF

Gene name from HGNC: CDKN2A (ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf)

HPA class: Cancer-related genes Disease related genes Human disease related genes Plasma proteins

AlphaFold DB: Q8N726

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/Q8N726

HPA link: https://www.proteinatlas.org/ENSG00000147889-CDKN2A

Tissue specificity RNA from HPA: Tissue enhanced (choroid plexus, pituitary gland)

Tissue expression from HPA: Mainly nuclear expression in most tissues.

Single cell type specificity Cell type enhanced (Late spermatids, Pancreatic endocrine cells, Early spermatids, Respiratory ciliated cells, Basal respiratory cells, Club cells)

Immune cell specificity: Immune cell enhanced (T-reg)

Subcellular summary HPA Located in Nucleoli (Single cell variability)

Cancer prognostic summary HPA Prognostic marker in endometrial cancer (unfavorable), renal cancer (unfavorable), liver cancer (unfavorable) and head and neck cancer (favorable)

Pathology link: https://www.proteinatlas.org/ENSG00000147889-CDKN2A/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000147889-CDKN2A/pathology/endometrial+cancer

OMIM: 600160

OMIM link2: https://www.omim.org/entry/600160

HGNC ID: HGNC:1787

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1787

Visulization